Posts Tagged: "patent office"

Hindsight Bias in Patent Examination: How Language Models Can Help

The patent examination process is subject to the well-known issue of hindsight bias. Issues with hindsight bias come up when a patent examiner, without realizing it, uses their knowledge of the invention itself to reject a claim as being obvious. If left unchecked, these issues can lead to incorrect determinations of obviousness, which prolong prosecution, cause unnecessary ex parte appeals to be filed, and force unfair narrowing of independent claims. However, even when an examiner learns about an invention that seems straightforward, human emotions and subjectivity can make it difficult for that examiner to appreciate that the invention was not obvious based on prior art that existed before the invention.

MSPB Grants ‘Corrective Action’ to APJ for USPTO Retaliation Following Whistleblower Activity

The Merit Systems Protection Board (MSPB) issued a decision on May 5 granting Patent Trial and Appeal Board (PTAB) Administrative Patent Judge (APJ) Michael Fitzpatrick’s request for corrective action with respect to alleged retaliatory personnel actions against him by senior management officials at the Department of Commerce and U.S. Patent and Trademark Office (USPTO). The 131-page decision said that Fitzpatrick filed the appeal to the MSPB in 2021, following punishment for “protected whistleblowing activity.

CAFC Reverses PTAB Decision that Invalidated Sanofi Injector Pen Patent

The U.S. Court of Appeals for the Federal Circuit (CAFC) issued a precedential decision Tuesday that reversed a Patent Trial and Appeal Board (PTAB) decision invalidating claims of Sanofi’s U.S. Patent No. RE47,614, which covers a drug delivery device. Mylan Pharmaceuticals petitioned the PTAB for inter partes review (IPR) of all 18 claims in Sanofi’s drug injector pen patent. The company argued the patent was invalid due to obviousness, and the PTAB agreed and invalidated the patent. However, Sanofi appealed to the CAFC and argued that Mylan failed to show that the previous patent was analogous to the ‘614 patent. The appeals court agreed with Sanofi because Mylan only argued that two prior patents were analogous and not the challenged patent.

The ‘Proposed Proposals’: USPTO Reiterates Nothing’s Set in Stone Yet on ANPRM

U.S. Patent and Trademark Office (USPTO) Director Kathi Vidal, Vice Chief Administrative Patent Judge (APJ) Michael Tierney of the Patent Trial and Appeal Board (PTAB) and Lead APJ Amber Hagy presented a webinar Tuesday on the Office’s Advance Notice of Proposed Rulemaking (ANPRM) on PTAB practices, walking attendees through some of the key proposals, and repeatedly reassuring stakeholders that the ANPRM does not contain any proposed rules. The widespread confusion about the ANPRM was highlighted during Vidal’s recent oversight hearing by the House IP Subcommittee.

European Inventor Award Finalists Focus on Sustainability

On Tuesday, the European Patent Office (EPO) announced the 12 inventors and inventor teams that have been selected as finalists for the 2023 European Inventor Award. The EPO placed three finalists each into four groups: Industry, Research, SMEs, and Non-EPO Countries. Members of the public can vote for the winner on the EPO’s website. The finalists hail from 12 countries, Australia, Austria, Belgium, China, Finland, France, Germany, Iceland, India, Ireland, Italy, and the United States. An independent jury of former European Inventor Award finalists used their expertise to select this year’s finalists.

USPTO’s ANPRM Sets the Stage for Latest Revamp of the Discretionary Denial Process

Between the precedential Fintiv decision in March of 2020 and Director Vidal’s Guidance Memo regarding the application of Fintiv in June of 2022, the discretionary denial rates of inter partes review (IPR) institution decisions under 35 U.S.C. § 314(a) plummeted from 40-50% to 11-16%. Coupled with the order issued by the Chief Judge of the Western District of Texas in July of 2022 declaring that all new patent cases filed in the Waco Division will be randomly assigned among the 12 judges in the district, the substantial decline in denials based on Fintiv in 2022 was not surprising. Now, amid speculations that Fintiv denial rates will increase once again, the USPTO recently announced a set of proposed rules on discretionary denial practice in an Advance Notice of Proposed Rulemaking (ANPRM).

Vidal Says PTAB Got it Wrong on Denial of Volvo IPR Due to District Court Invalidation

United States Patent and Trademark Office (USPTO) Director Kathi Vidal issued a sua sponte Director Review decision on Tuesday explaining that the Patent Trial and Appeal Board’s (PTAB’s) reading of the inter partes review (IPR) statute was incorrect, and directing the Board to revisit a petition brought by Volvo Penta of the Americas, LLC and to analyze the Fintiv factors in view of a parallel district court proceeding.

House IP Subcommittee Suggests Vidal is Overstepping with Advance PTAB Proposals

Today’s hearing of the House Judiciary Subcommittee on Courts, Intellectual Property and the Internet on Oversight of the U.S. Patent and Trademark Office (USPTO) demonstrated some confusion on the part of Congress about the intent of USPTO Director Kathi Vidal’s recent Advanced Notice of Proposed Rulemaking (ANPRM) on changes to Patent Trial and Appeal Board (PTAB) processes, and suggested the Subcommittee members believe she may be exceeding her authority.

Patent Filings Roundup: Slow Board Week Highlights Reduced Use of PTAB; Acacia and IV Sue, Settle, and are Challenged in Ongoing Campaigns; Advisory ANPRM on Fintiv Changes Drops

It was another low patent-filing week at the Patent Trial and Appeal Board (PTAB), with just 12 new petitions (about half of last year’s average); district court filings were average with 47 new filings. Acacia subsidiary Atlas Global received more petitions on patents that are part of its broad assertion campaign; some Centripetal patents were instituted by a defendant in that going campaign; Intellectual Ventures appears to have settled the latest round of automotive litigation before Judge Albright, ending that case; and IP Edge continues to not file new cases and settle old ones, in the wake of the end of the year discovery battles. Zillow was instituted on patents IBM had asserted or threatened; and the Vidal administration is the latest recipient of yet another Gil Hyatt suit.

Speakers Conflict on Urgency of USPTO Changes to Accommodate AI in Invention Process

The U.S. Patent and Trademark Office (USPTO) held its East Coast Listening Session on AI Inventorship today, featuring both USPTO staff and patent stakeholder speakers contemplating possible approaches to patenting in a world in which generative artificial intelligence (AI) almost seems to have snuck up on everyone. While many speakers cautioned against moving too quickly to change the rules for AI-generated inventions, others warned that doing nothing could result in chaos for the USPTO and grave economic and innovation losses for the country.

Killian Petitions Supreme Court to End Alice/Mayo

Jeffrey Killian yesterday submitted a petition for writ of certiorari to the United States Supreme Court asking the Court to provide clear guidance on or else throw out the Alice/Mayo test for patent eligibility. Killian is involved in an ongoing patent dispute in which the Patent Trial and Appeal Board (PTAB) rejected claims of his  U.S. Patent Application No. 14/450,042 under Section 101. The U.S. Court of Appeals for the Federal Circuit (CAFC) affirmed the ruling in August 2022. In the petition, Killian claims that the U.S. Patent and Trademark Office (USPTO) violated Supreme Court precedent by ruling the patent application ineligible under the Alice/Mayo test.

Post-Vivint Patent Office Treatment of Ex Parte Reexaminations After Non-Instituted IPRs

Given the various ways the Patent Trial and Appeal Board (PTAB) can exercise discretion to deny institution of an inter partes review (IPR) petition (and the corresponding non?appealability of those decisions), ex parte reexamination is becoming an attractive option to challenge patent validity following a decision not to institute. Because a later filed ex parte reexamination is often viewed as a “second bite at the apple,” there were questions as to how the U.S. Patent and Trademark Office (USPTO) should treat these second attempts at invalidating a patent. For IPRs, the PTAB has used several bases for discretionary denial of a later-filed IPR, but those bases were not being applied to follow-on ex parte reexamination requests. However, in In re Vivint, the Federal Circuit held that the USPTO has the authority to discretionarily deny an ex parte reexamination request under 35 U.S.C. § 325(d), i.e., if “the same or substantially the same prior art or arguments previously were presented to the Office.”

Supreme Court Dodges AI Inventor Question with Denial of DABUS Case

One day before the U.S. Patent and Trademark Office (USPTO) is set to hold its first public listening session on AI inventorship, the U.S. Supreme Court today denied certiorari in the case of Thaler v. Vidal, which asked the Court to consider the question: “Does the Patent Act categorically restrict the statutory term ‘inventor’ to human beings alone?” Dr. Stephen Thaler lost his case at the U.S. Court of Appeals for the Federal Circuit (CAFC) last August, when the CAFC said the USPTO’s reading of the statute as clearly referring to inventors as natural person was “unambiguously” correct.

USPTO Preliminary Proposals on Discretionary Denial Include Curbing ‘For-Profit, Non-Competitive Entities’ Use of IPR

The U.S. Patent and Trademark Office (USPTO) today published an Advanced Notice of Proposed Rulemaking (ANPRM) indicating it is considering changes to America Invents Act (AIA) proceedings before the Patent Trial and Appeal Board (PTAB). Perhaps most notably, one of the proposals it is asking for input on has to do with creating rules that would authorize discretionary denial of inter partes review (IPR) proceedings “to ensure that certain for-profit, non-competitive entities do not use the IPR and PGR processes in ways that do not advance the mission and vision of the USPTO to promote innovation or the intent behind the AIA to improve patent quality and limit unnecessary and counterproductive litigation costs.”

USPTO Director Scolds VLSI for Publicly Citing Anonymous Report on PQA-Intel Connection

U.S. Patent and Trademark Office (USPTO) Director Kathi Vidal said in an Order filed yesterday in IPR2021-01229 between Patent Quality Assurance (PQA)/Intel and VLSI Technology that VLSI’s reference in its Rehearing Request to an “unsolicited, anonymous, and improper ex parte communication” about the relationship between PQA and Intel that Vidal had put under seal has put VLSI on thin ice and in danger of being sanctioned.